Michael J. Detke
Chief Medical Officer at Cortexyme, a clinical-phase biotechnology company developing therapeutics targeting a specific pathogen tied to neurodegeneration, for the treatment of Alzheimer’s and potentially other degenerative disorders.
A clinical drug development scientist and executive with research experience since 1986, in biotech/pharma research since 1999. Board-certified Psychiatrist teaching/supervising medical students and residents in patient care part-time as an adjunct Clinical Professor of Psychiatry at Indiana University School of Medicine since 2000.
In prior biotech roles, CMO at Embera NeuroTherapeutics; led clinical development of a novel combination drug for the treatment of addictions, with lead indications of cocaine & tobacco use disorders. As CoMentis CMO, led clinical development of molecules targeting the alpha7 receptor for Alzheimer’s Disease and Cognitive Impairment Associated with Schizophrenia. As MedAvante CMO, led a team dedicated to improving signal detection in CNS clinical trials, collaborating with CNS pharmaceutical companies, biotechs, NIMH, the VA, etc.
As Executive Director for Neuroscience Medical Research at Lilly Research Laboratories in Indianapolis, oversaw all CNS assets in early phase development, including all psychiatric, neurological, and pain indications. Previously at Lilly, Senior Medical Director responsible for Phase III development for Cymbalta (depression, anxiety and multiple pain indications) and Phase IV for Prozac, and a Clinical Research Physician in late-phase development.
Educated at Yale University and the University of Pennsylvania, and trained in psychiatry at Harvard Medical School. Over 70 manuscripts published in peer-reviewed journals, and an active member of scientific organizations such as ACNP, ASCP and SOBP.